You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PTCL

Showing 26 - 50 of 258
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Treatment, Peripheral T-cell Lymphoma Trial in Beijing (liposomal mitoxantrone HCl, gemcitabine, dexamethasone, and cisplatin)

Recruiting
  • Treatment
  • Peripheral T-cell Lymphoma
  • liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin
  • Beijing, China
  • +4 more
Jun 28, 2022

Peripheral T-cell Lymphomas (PTCL) Trial in Taiwan (Lenalidomide and Gemcitabine (Dose level 11), Lenalidomide and Gemcitabine

Not yet recruiting
  • Peripheral T-cell Lymphomas (PTCL)
  • Lenalidomide and Gemcitabine (Dose level 11)
  • +3 more
  • Kaohsiung, Taiwan
  • +3 more
Nov 1, 2021

Treatment-naïve, Peripheral T Cell Lymphoma Trial in Guangzhou (Dose-finding stage: Liposomal mitoxantrone HCl,

Recruiting
  • Treatment-naïve
  • Peripheral T Cell Lymphoma
  • Dose-finding stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone
  • Dose-expansion stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Jul 26, 2021

Lymphoma, T-Cell, Peripheral Trial in Czechia (Adcetris 50 MG Injection, Endoxan, Doxorubicin)

Not yet recruiting
  • Lymphoma, T-Cell, Peripheral
  • Adcetris 50 MG Injection
  • +4 more
  • Brno, Czechia
  • +6 more
Aug 26, 2021

Lymphoma, T-Cell Trial in Charlottesville (Durvalumab, Pralatrexate, Romidepsin)

Recruiting
  • Lymphoma, T-Cell
  • Charlottesville, Virginia
    University of Virginia
Mar 16, 2022

Relapsed/Refractory Peripheral T-cell Lymphoma Trial in Fairport (Tolinapant, Decitabine + Cedazuridine)

Recruiting
  • Relapsed/Refractory Peripheral T-cell Lymphoma
  • Aurora, Colorado
  • +2 more
Jan 3, 2023

Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)

Active, not recruiting
  • Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)
  • Yamagata, Japan
    Yamagata University Hospital
Feb 21, 2022

Peripheral T-cell Lymphoma Trial in Worldwide (Duvelisib)

Active, not recruiting
  • Peripheral T-cell Lymphoma
  • Duarte, California
  • +27 more
May 3, 2022

Peripheral T-cell Lymphoma Trial in Beijing (Sintilimab, Chidamide, Azacidine)

Not yet recruiting
  • Peripheral T-cell Lymphoma
  • Beijing, Beijing, China
    Beijing
Mar 5, 2021

Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL) Trial in Augusta, Nashville, Houston

Recruiting
  • Mantle Cell Lymphoma
  • +9 more
  • L-Bcl-2 antisense oligonucleotide
  • Augusta, Georgia
  • +2 more
Nov 18, 2022

Non-Hodgkin's Lymphoma (NHL), Peripheral T Cell Lymphoma (PTCL) Trial in Tianjin (Ex-vivo expanded allogeneic ?dT cells)

Recruiting
  • Non-Hodgkin's Lymphoma (NHL)
  • Peripheral T Cell Lymphoma (PTCL)
  • Ex-vivo expanded allogeneic γδT cells
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Disease Hospital
Jan 5, 2021

Peripheral T-Cell Lymphoma Trial in Worldwide (SP-02L (darinaparsin for injection))

Completed
  • Peripheral T-Cell Lymphoma
  • SP-02L (darinaparsin for injection)
  • Hong Kong, Hong Kong
  • +23 more
Jul 22, 2021

Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL) Trial in United States (KT-333)

Recruiting
  • Non Hodgkin Lymphoma (NHL)
  • +4 more
  • Orange, California
  • +8 more
Nov 29, 2022

T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory Trial in Italy (Venetoclax)

Active, not recruiting
  • T-Cell Lymphoma Relapsed
  • T-Cell Lymphoma Refractory
  • Aviano, Italy
  • +12 more
Dec 20, 2022

Peripheral T-cell Lymphoma Trial in Worldwide (brentuximab vedotin, cyclophosphamide, doxorubicin)

Recruiting
  • Peripheral T-cell Lymphoma
  • brentuximab vedotin
  • +3 more
  • Birmingham, Alabama
  • +45 more
Jan 4, 2023

Peripheral T Cell Lymphoma Trial in Guangzhou (Mitoxantrone Hydrochloride Liposome Injection, Chidamide)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • Mitoxantrone Hydrochloride Liposome Injection
  • Chidamide
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Dec 11, 2020

Peripheral T Cell Lymphoma Trial (F520)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • (no location specified)
Oct 19, 2020

T-Cell Lymphoma Relapsed, Adult T-Cell Leukemia (ATL), Peripheral T-Cell Lymphoma (PTCL) Trial run by the NCI (IL-15 plus,

Completed
Has Results
  • T-Cell Lymphoma Relapsed
  • +4 more
  • IL-15 plus
  • alemtuzumab
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Apr 27, 2022

Relapsed/Refractory Peripheral T-cell Lymphoma, Relapsed/Refractory Classical Hodgkins Lymphoma Trial in Worldwide (AZD4573)

Recruiting
  • Relapsed/Refractory Peripheral T-cell Lymphoma
  • Relapsed/Refractory Classical Hodgkins Lymphoma
  • Duarte, California
  • +33 more
Jan 5, 2023

Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular T-Cell

Recruiting
  • Recurrent Angioimmunoblastic T-Cell Lymphoma
  • +13 more
  • Brentuximab Vedotin
  • Pembrolizumab
  • Chicago, Illinois
    Northwestern University
Jun 15, 2022

Lymphatic Diseases Trial in Italy (Brentuximab Vedotin, Bendamustine)

Terminated
  • Lymphatic Diseases
  • Bologna, BO, Italy
  • +4 more
May 26, 2021

Lymphoma, T-Cell, Peripheral Trial in United States (Romidepsin, Ixazomib)

Active, not recruiting
  • Lymphoma, T-Cell, Peripheral
  • Chicago, Illinois
  • +6 more
Jan 15, 2021

Peripheral T-cell Lymphoma Trial in Beijing, Shanghai (TQ-B3525)

Unknown status
  • Peripheral T-cell Lymphoma
  • Beijing, Beijing, China
  • +1 more
Oct 30, 2020

Relapsed or Refractory Peripheral T Cell Lymphoma Trial in Worldwide (AZD4205)

Recruiting
  • Relapsed or Refractory Peripheral T Cell Lymphoma
  • New Haven, Connecticut
  • +50 more
Jan 27, 2022

Peripheral T Cell Lymphoma Trial in Beijing (GB226)

Recruiting
  • Peripheral T Cell Lymphoma
  • GB226
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Mar 2, 2021